Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025524 | 1.00 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL1111537 | 0.82 | SLC6A3 (0.40) | — | |
| SCHEMBL1111535 | 0.82 | SLC6A3 (0.40) | — | |
| SCHEMBL2000021 | 0.81 | — | — | |
| SCHEMBL4028733 | 0.80 | CTSC (0.31) | — | |
| SCHEMBL1111572 | 0.77 | — | — | |
| SCHEMBL1111568 | 0.77 | — | — | |
| SCHEMBL5168798 | 0.74 | — | — | |
| SCHEMBL3366060 | 0.74 | — | — | |
| SCHEMBL7956129 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7223746-B2 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1438104-B1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022726-B2 | ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1442033-B1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1442033-A1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | Allergan, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1438104-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | Allergan, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC. | 2004-06-03 | — | — | US | disclosed |
| US-6710072-B2 | VISION DEFECTS | ALLERGAN, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2003040126-A1 | φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037433-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6376533-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 390/4885 |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | HSD11B1 337/4885 |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER4, PTGER2, LTB4R2 | HSD11B1 321/4885 |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.